Financial Performance Highlights

Q2 FY27 Results (Quarter Ending September 30, 2026):

  • Revenue: INR 507 crores (22% decline YoY)
  • Cost of Goods Sold: INR 34 crores (approximately 7% of revenue)
  • Employee Expenses: INR 321 crores
  • Other Expenses: INR 105 crores (23% decline YoY)
  • EBITDA: INR 46 crores
  • Depreciation: INR 90 crores
  • Finance Cost: INR 40 crores

H1 FY27 Results (Half Year Ending September 30, 2026):

  • EBITDA: INR 106 crores
  • Depreciation: INR 181 crores

Segment-wise Performance:

CDMO Business:

  • Q2 Revenue: INR 388 crores (vs. INR 509 crores YoY)
  • H1 Revenue: INR 929 crores (vs. INR 1,120 crores YoY)
  • Q2 Margin: 12.3% (vs. 25% YoY)
  • H1 Margin: 8.7% (vs. 21% YoY)

Marketable Molecules Segment:

  • Q2 Revenue: INR 118 crores (vs. INR 143 crores YoY)
  • H1 Revenue: INR 256 crores (vs. INR 240 crores YoY)

Operational and Strategic Updates

Market Conditions and Business Development:

  • Market trends remain challenging but showing slight upward trend in early-phase projects
  • Customers awaiting funding for early-phase programs
  • Potential shift of venture capital from AI to pharmaceutical industry expected
  • Company participated in multiple exhibitions (CPHI Milan, Festival of Biologics, BioJapan)
  • Acquired significant projects in early clinical phase and clinical Phase II

Integration and Technology Transfers:

  • Close interaction between Carbogen Amcis and Dishman India intensively promoted
  • Multiple processes being transferred from Carbogen to Dishman India
  • Two major technology transfers underway:
  • First transfer: American company legacy product, on schedule for completion by end of FY27
  • Second transfer: Expected to cover two additional pipeline products in upcoming year
  • Combined annual revenue potential: CHF 25-30 million
  • 9 senior employees from Carbogen Amcis Europe visiting India sites over four weeks

Facility and Infrastructure Updates:

  • DCAL sites in Bavla and Naroda experiencing significant increase in audits and customer visits
  • Received regulatory approvals including FDA and government NDA
  • EDQM certificate of suitability granted
  • New U.S. Drug Master File and letter of authorization submitted
  • Largest BWT Switzerland purifying water plants in India completed at Bavla
  • State-of-the-art infrastructure with largest distribution network and user points

Specific Project Highlights:

  • Japanese innovator molecule co-investment expansion project on track
  • Expected to go live in next financial year
  • Revenue potential: CHF 15-20 million annually
  • Naroda facility supported launch of macrocyclic peptide in U.S. market
  • First commercial contract secured after July 2026 market approval
  • Semiconductor project: Customer requested quotation for initial volume of several 100 metric tons
  • Soft gel drug product operations experiencing significant business interest

Sales and Market Expansion:

  • Increasing commercial team with focus on U.S. markets
  • South American market expansion showing successes with new customers and orders
  • Strong vitamin D & analogues sales with high margins, especially Calcifediol
  • Halal certification in process at Veenendaal to access Asian markets

Capital Expenditure and Financing

Capital Expenditure:

  • Q2 CapEx: $5.4 million
  • H1 CapEx: $10.3 million
  • Full-year guidance: Approximately INR 200 crores
  • Includes maintenance CapEx and digital transformation initiatives (SAP implementation)

External Commercial Borrowing (ECB):

  • CHF 200 million ECB in process
  • First tranche of approximately $50 million expected before Christmas holidays or in Q4 FY27
  • Upon completion, expected reduction in quarterly interest cost from INR 40 crore to INR 20-25 crore
  • Currently completing final conditions precedents and tax opinions

Cash Position and Debt:

  • Cash balance: Approximately INR 1,000 crores
  • Net debt: Approximately $165 million at consolidated level
  • Recent NCD raising at ~10% primarily for refinancing existing NCDs and maintenance CapEx

Guidance and Outlook

Revenue Outlook:

  • FY27: No growth expected compared to FY26 revenue of INR 2,900 crores
  • Medium-term (FY28-29): 10-12% annual growth expected
  • Bavla facility: Expected revenue of INR 400-450 crores for full FY28

Margin Outlook:

  • FY27 EBITDA margin: Approximately 15-16%
  • Medium-term (FY28-29): EBITDA margin expected to exceed 20-21%

Operational Outlook:

  • Expect recovery in second half FY27 for vitamin D analogs business
  • Development pipeline increased from CHF 89 million to CHF 98 million
  • 12+ late-phase projects including PPQ campaigns in portfolio
  • Three commercial products added in current calendar year
  • Increased orders from existing commercial products

Risk Factors and Challenges

  • Business nature described as "lumpy" with dependency on molecule development timing
  • Biotech funding constraints affecting early-phase development revenue
  • Regulatory filing changes required for technology transfers take time
  • Fixed cost structure makes EBITDA sensitive to revenue fluctuations
  • Multi-jurisdictional complexities in ECB funding process